Prostamax
Lys-Glu-Asp-Pro Prostate Bioregulator
Evidence grade 1 of 5, Untested. Read how the Atlas grades evidence.
Prostamax is the synthetic Khavinson tetrapeptide KEDP (Lys-Glu-Asp-Pro, CAS 473578-47-1) and rests only on preclinical Russian data (rat prostatitis models and prostate cell cultures showing reduced inflammation and reparative signals) from the originating St. Petersburg Institute of Bioregulation and Gerontology. There are no Western randomized controlled trials of synthetic KEDP, no independent replication, and no registered human trials on ClinicalTrials.gov or the EU register. The human clinical literature the current entry credits (3 RCTs) belongs to the older bovine prostate EXTRACT drug Prostatilen/Vitaprost, not to the defined single-sequence peptide, so an animal-only grade 1 is the honest grade for Prostamax itself.
- FDA
- No FDA approval; not an FDA-approved drug and sold in the US only as a research chemical labeled not for human consumption. Not an EMA-approved medicine. (Separately, the related bovine extract Prostatilen/Vitaprost is registered as a medicine in Russia, not in the US or EU.)
- WADA
- Not listed by name on the WADA Prohibited List.
Reference only. Not medical advice.
What can go wrong
Unapproved research chemical; evidence for synthetic KEDP is animal/cell-only with no human safety, pharmacokinetic or toxicology data and no Western replication.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about Prostamax. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
Prostamax is the synthetic Khavinson tetrapeptide KEDP (Lys-Glu-Asp-Pro), the defined-sequence successor to the Russian bovine prostate extract Prostatilen/Vitaprost; it is associated in preclinical Russian rat and cell-culture models with reduced prostate inflammation and reparative signals, but it has no Western RCTs, no independent replication and no FDA or EMA approval.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Prostamax is a prostate-directed peptide bioregulator, related to the Russian prostate preparation Prostatilen, promoted to support prostate function. Prostatilen-class products have a Russian clinical tradition in prostate conditions, but the specific bioregulator claims are unproven in independent Western trials.
Prostamax is a prostate-targeted bioregulator from the Khavinson system, offered in the family’s natural-extract and defined-peptide forms, part of the same organ-by-organ lineup as the reproductive peptide Testagen.
- Type
- Prostate bioregulator
- Target
- Prostate
- Use
- Pulsed courses
- Origin
- St. Petersburg institute
- Evidence
- Preclinical and Russian
- Western RCT
- None
The Prostate Label On A Single-Lineage Peptide System
Prostamax follows the family template, with one added caution worth stating plainly. Its mechanism and evidence are the family’s: a contested gene-regulation proposal and preclinical, Russian, single-lineage support with no independent human trials. The added caution is clinical, because prostate symptoms in older men can signal conditions, including cancer, that require timely medical evaluation. Using a gray-market prostate peptide to self-manage urinary or prostate symptoms risks delaying a diagnosis that matters. Prostamax is another unconfirmed tissue-labeled bioregulator, in a domain where self-treatment can be actively harmful through delay.
Safety in detail
No published human pharmacokinetic, toxicology or clinical-safety data exist for synthetic Prostamax (KEDP); Western product is research-grade material sold not for human consumption, and any human clinical support in the older entry actually pertains to the separate bovine extract Prostatilen.
- Reported safety in decades of Russian clinical use is described as clean, with few serious adverse events, but that record comes largely from within the same research tradition that developed the peptides and has not been independently verified in Western trials.
- Long-term safety in rigorous, controlled human studies is essentially uncharacterized outside that tradition.
- Most material sold internationally is gray-market or supplement-grade, so unverified identity, dose and purity are the dominant practical risks.
- Not FDA-approved for any use; claims of disease treatment are not supported by Western regulatory review.
Children and teenagers
Prostamax has no pediatric relevance or appropriate use.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Prostamax reaches users only through the bioregulator gray market and longevity vendors, with no approved product.
How we got here
Prostamax descends from the Russian prostate-peptide program begun in the 1980s at the St. Petersburg (Leningrad) Institute of Bioregulation and Gerontology under Vladimir Khavinson. The first-generation product was a bovine-prostate polypeptide extract, registered in Russia as Prostatilen (with brand variants Vitaprost as suppositories and the oral Cytomax capsule Libidon), which accumulated the roughly 30 years of Russian clinical use for chronic prostatitis and BPH. Prostamax is the later, defined single-sequence tetrapeptide (KEDP) marketed as the synthetic successor to that extract, and the two should not be conflated: the human clinical evidence sits with the extract while the isolated peptide has only preclinical animal and cell-culture data. Outside Russia it circulates mainly as an unapproved research chemical rather than a registered medicine.
Prostamax was developed within the Khavinson bioregulator program at the St. Petersburg institute as the prostate-targeted member of the organ peptide system.
The numbers behind the grade
- Type
- Prostate peptide
- Target
- Prostate
- Russia
- Prostatilen tradition
- FDA
- Not approved
- Evidence
- Single-tradition
- Western RCTs
- None
The people taking it
A prostate-support bioregulator, linked to the better-known Russian preparation Prostatilen.
Prostamax’s users are older men focused on prostate and urinary health within the longevity and bioregulator-protocol community.
Used for prostate support within the Russian peptide tradition and among international longevity users; not independently validated.
Set against the alternatives
Prostamax is the prostate counterpart to the reproductive peptide Testagen within the same system. Its support is preclinical and single-lineage, unlike evidence-based urology, and the cancer-surveillance stakes make the contrast especially important.
What we do not know
- Whether independent, Western randomized trials confirm any of the claimed clinical effects.
- Whether the proposed DNA-binding, gene-regulating mechanism actually operates in human tissue at the doses used.
- Why, after forty years and hundreds of papers, replication outside the originating institute remains so limited.
- Whether results from complex tissue extracts (Cytomaxes) translate to the defined synthetic peptides (Cytogens) sold alongside them.
Legal status
Not FDA-approved for any indication in the United States. Several related bioregulators are registered pharmaceuticals in Russia, where they are used clinically, but that approval does not carry to the US or EU. The first formal FDA advisory-committee evaluation of a Khavinson peptide (Epitalon) is scheduled for July 2026. Internationally it is sold as a Cytogen or Cytomax supplement and as a research chemical.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Available internationally as oral or injectable bioregulator supplements (Cytogen and Cytomax lines) and as research-use-only peptide vials, with legal status varying by country. None is an FDA-approved medicine, so there is no regulated US prescription route; the honest course is to treat the claims with caution and consult a clinician.
Material reaches international buyers two ways: as branded Cytogen (synthetic) or Cytomax (animal-tissue extract) supplements produced in Russia, and as research-use-only vials, much of it synthesized in China. Neither route guarantees the identity or potency the label claims, so an independent certificate of analysis is the only real check and is uncommon.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Prostamax.
- Timeline. We have not built the dated record of research and regulatory events.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
Sources
Prostamax is the synthetic Khavinson tetrapeptide Lys-Glu-Asp-Pro (KEDP), CAS 473578-47-1, described as the defined-sequence successor to the bovine extracts Prostatilen and Vitaprost; no FDA/EMA approval, no Western RCTs and no independent replication outside the originating institute
Prostatilen is a bovine-prostate polypeptide bioregulator with a documented 30-year record of clinical use in Russia for chronic prostatitis and benign prostatic hyperplasia; this review is the human-evidence base that belongs to the extract, not to synthetic KEDP
Vitaprost Forte (Prostatilen-based prostate extract) evaluated in patients with benign prostatic hyperplasia, describing pathogenetic basis and clinical results in Russian urology practice
Vitaprost Forte in the treatment of patients with BPH (ResearchGate record)
Bioregulatory therapy for chronic abacterial prostatitis using prostate polypeptide preparations, documenting the Russian clinical use pattern for this class
Prostamax is sold as a synthetic 20 mg research-chemical vial labeled for laboratory research and not for human consumption, confirming its unapproved research-chemical marketing status in the West
Prostamax described as a synthetic Khavinson KEDP tetrapeptide studied only in laboratory settings, with preclinical mechanism claims (chromatin/epigenetic regulation) and no human clinical validation
Prostamax marketed as a Khavinson prostate bioregulator peptide for prostate-support research use, confirming brand/vendor naming and research-only positioning
Libidon is the oral (Cytomax) prostate peptide capsule in the same Russian prostate-bioregulator lineage, referencing St. Petersburg Institute prostate work; establishes the sibling oral product and shared institutional origin
Independent overview of Prostamax as synthetic KEDP, noting preclinical-only status, absence of registered human trials and lack of published human pharmacokinetic or toxicology data
The studies that matter
Russian prostate-peptide studies1990s-2000s
Prostatilen-class preparations were studied and used in Russia for prostate conditions, the basis for prostate bioregulator claims.
Independent replicationlimited
Rigorous independent Western trials of Prostamax specifically are lacking.